- Trials with a EudraCT protocol (887)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
887 result(s) found for: Cervical pregnancy.
Displaying page 1 of 45.
EudraCT Number: 2008-007763-16 | Sponsor Protocol Number: 1.0 | Start Date*: 2009-05-06 | ||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie | ||||||||||||||||||
Full Title: Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
Medical condition: Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006946-24 | Sponsor Protocol Number: NV25025 | Start Date*: 2009-12-10 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high... | ||||||||||||||||||
Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2018-002965-20 | Sponsor Protocol Number: MISFOL2018 | Start Date*: 2019-05-14 | |||||||||||
Sponsor Name:SOLEDAD CARREGUI, NATIVIDAD BANEGAS, SARA CRUZ | |||||||||||||
Full Title: A randomized, open, 2 treatment arms clinical trial to evaluate the efficacy and safety of cervical ripening with Foley catheter vs cervical ripening with intravaginal synthetic analogue of prostag... | |||||||||||||
Medical condition: Cervical ripening prior labor induction | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000456-15 | Sponsor Protocol Number: 3518 | Start Date*: 2015-05-19 | |||||||||||
Sponsor Name:Kings College London [...] | |||||||||||||
Full Title: The prevention of pre-term birth in women who develop a short cervix. A multi-centre randomised controlled trial to compare three treatments; cervical cerclage, cervical pessary and vaginal proges... | |||||||||||||
Medical condition: Short Cervix in Pregnancy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003410-18 | Sponsor Protocol Number: MRZ 60201-0605/1 | Start Date*: 2007-09-07 | |||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: Prospective, single-arm, multicenter trial to investigate the efficacy and safety of NT 201 (botulinum neurotoxin type A free of complexing proteins) and the duration of treatment effect after one ... | |||||||||||||
Medical condition: Cervical dystonia, predominantly rotational spasmodic torticollis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003413-25 | Sponsor Protocol Number: GCT1015-04 | Start Date*: 2018-03-07 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A single arm, multicenter, international trial of tisotumab vedotin (HuMax®-TF-ADC) in previously treated, recurrent or metastatic cervical cancer | |||||||||||||
Medical condition: recurrent or metastatic cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019657-18 | Sponsor Protocol Number: 1.0 | Start Date*: 2010-06-04 | ||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie | ||||||||||||||||||
Full Title: Topical Imiquimod in Treating Patients with Persistent HPV-Infection after Surgical or Radiation Treatment of Cervical Cancer | ||||||||||||||||||
Medical condition: Patients with positive high risk HPV-test 6 months after surgical or radiation treatment for cervical cancer are eligible for this trial. After signing informed consent patients are randomized to H... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005578-12 | Sponsor Protocol Number: 08-PIR-06 | Start Date*: 2009-03-02 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanc... | |||||||||||||
Medical condition: Patients with Metastatic or Locally Advanced Cervical Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002271-34 | Sponsor Protocol Number: GINECO-CE108b | Start Date*: 2020-02-13 | ||||||||||||||||||||||||||
Sponsor Name:ARCAGY-GINECO | ||||||||||||||||||||||||||||
Full Title: A multicenter, pilot study evaluating immune impact and safety of nivolumab in combination with ipilimumab (immune combination) before initial RT-CT treatment for cervix cancer. COLIBRI Study | ||||||||||||||||||||||||||||
Medical condition: Patients with cervical squamous cell carcinoma stage IB3 to IVa | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006449-14 | Sponsor Protocol Number: MedAff-BTX-0616 | Start Date*: 2008-06-20 |
Sponsor Name:Allergan Inc. | ||
Full Title: Multicenter, Double-Blind, Randomized, Controlled, Parallel Comparison of Efficacy and Safety of Fixed Doses of Two Formulations of Botulinum Toxin Type A in the Treatment of Moderate to Severe Ce... | ||
Medical condition: Moderate to Severe Cervical Dystonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001655-39 | Sponsor Protocol Number: GCT1015-07 | Start Date*: 2021-08-17 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Versus Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer | |||||||||||||
Medical condition: Second- or Third-Line Recurrent or Metastatic Cervical Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NO (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) DK (Completed) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001440-53 | Sponsor Protocol Number: MK3475-826 | Start Date*: 2019-01-08 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or ... | |||||||||||||
Medical condition: Cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) ES (Completed) PL (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000236-27 | Sponsor Protocol Number: VEG105281 | Start Date*: 2006-12-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Montherapy and Lapatinib Monotherapy in Subjects with FI... | |||||||||||||
Medical condition: Patients with FIGO Stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IE (Completed) FR (Completed) EE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004119-36 | Sponsor Protocol Number: METOXY-LACC | Start Date*: 2019-11-04 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Altered tumor oxygenation by Metformin, a potential step in overcoming radiotherapy resistance in locally advanced cervical cancer. | |||||||||||||
Medical condition: Locally advanced cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002035-26 | Sponsor Protocol Number: 115411 | Start Date*: 2011-10-21 | |||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||||||||||||
Full Title: A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent ... | |||||||||||||||||||||||
Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) SE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001300-35 | Sponsor Protocol Number: UCL11/0034 | Start Date*: 2012-01-31 | ||||||||||||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||||||||||||
Full Title: A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer | ||||||||||||||||||||||||||||
Medical condition: Locally advanced cervical cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005465-41 | Sponsor Protocol Number: CERVANTES | Start Date*: 2022-03-17 | |||||||||||
Sponsor Name:CEEGOG reg. ass. | |||||||||||||
Full Title: An international randomised trial of radical surgery followed by adjuvant (chemo)radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer patients | |||||||||||||
Medical condition: early-stage, intermediate-risk cervical cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003622-33 | Sponsor Protocol Number: 2017/2608 | Start Date*: 2018-04-03 | ||||||||||||||||
Sponsor Name:Gustave Roussy | ||||||||||||||||||
Full Title: Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer | ||||||||||||||||||
Medical condition: Locally Advanced Cervical Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001325-14 | Sponsor Protocol Number: 580299/008 | Start Date*: 2004-08-12 |
Sponsor Name:GlaxoSmithKline SA | ||
Full Title: Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatit... | ||
Medical condition: cervical cancer => study is conducted in healthy female | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-005987-15 | Sponsor Protocol Number: The Triple P study | Start Date*: 2009-10-22 | |||||||||||
Sponsor Name:AMC Amsterdam | |||||||||||||
Full Title: Preventing preterm birth: Costs and effects of screening of healthy women with a singleton pregnancy for a short cervical length. | |||||||||||||
Medical condition: Preterm birth with healthy singleton pregnancies | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
